IgYssentiel^®: Polyclonal Immunoglobulin Y (IgY), a breakthrough natural solution to strengthen immunity and combat infections

IgYssentiel^® is an exclusive active ingredient developed by Laboratoire THERASCIENCE. These polyclonal Immunoglobulin Y (IgY) antibodies represent an unprecedented innovation in physionutrition for the prevention and management of infections. As a true multi-target defense barrier based on passive immunity, IgYssentiel^® has demonstrated efficacy against a wide range of pathogens — including bacteria, viruses, fungi, and parasites — through a fast, local, and specific mode of action.

Naturally derived from egg yolk, IgYssentiel^® is produced using a patented process that ensures an exceptional purity of 99% — 500 times higher than other IgY products on the market. Our IgY antibodies are stable, non-toxic, and resistant to pancreatic enzymes.

Moreover, IgYssentiel^® is delivered in 100% plant-based gastro-resistant capsules, ensuring maximum protection and efficacy.

 

Mechanisms of Action of IgYssentiel^®

IgYssentiel^® provides protection not only for the gastrointestinal tract, but also for the oral and respiratory mucosa.
When pathogens are present, IgY antibodies bind to these microorganisms, preventing them from adhering to mucous membranes and epithelial surfaces.

Thanks to its targeted mechanisms of action, IgYssentiel^® :

- Inhibits microbial adhesion to epithelial cell surfaces

- Prevents viral colonization by blocking cell-to-cell spread

- Promotes bacterial agglutination, leading to microbial immobilization and death, or facilitating their elimination through the intestinal tract

- Inhibits enzymatic activity

- Neutralizes bacterial toxins.

 

Although IgY antibodies are structurally similar to human IgG, they do not activate the complement system of the innate immune response, thereby preventing non-specific inflammation.

 

 

Efficiency of IgYssentiel^®  

The polyclonal IgY antibodies in IgYssentiel^® target a wide range of pathogens responsible for oral, respiratory, and digestive infections, including E. coli, Salmonella spp., Helicobacter pylori, Enterococcus faecalis, Enterococcus faecium, Klebsiella pneumoniae, Shigella flexneri, and Pseudomonas aeruginosa.

IgYssentiel^® also contains specific IgY antibodies, directed against inflammation-related molecules such as gliadin (implicated in gluten intolerance), bacterial toxins like LPS (lipopolysaccharide), and bacterial motility factors like flagellin — all of which are associated with digestive, immune, and metabolic disturbances.

For instance, IgYssentiel^® has demonstrated its efficacy in respiratory infections.
A randomized, double-blind, placebo-controlled clinical study conducted in 28 healthy individuals showed that a 3-month supplementation with polyclonal IgY antibodies reduced the duration, incidence, and severity of respiratory tract infections by 60%⁽¹⁾.

With its unique mechanism of action, broad-spectrum activity, and excellent safety profile, IgYssentiel^® represents a cutting-edge approach to the management of infectious and inflammatory diseases — while supporting the preservation of a healthy gut microbiota.

 

 

 

(1) Recher S et al, A two-arm randomized, double-blind, placebo-controlled, pilot study to evaluate the 
effects of Muno-IgYTM on immune function in healthy adult volunteers, 2023.